Formulation&Evaluation of Anti-Hypercholesteremia Drugs (Ezetimibe&Atorvastatin) In Different solid dosage forms

It is estimated that almost 20 million people will die from cardiovascular diseases by 2015. The most common manifestation of cardiovascular diseases is coronary heart disease .One of the modifiable risk factors for CHD is hypercholesterolemia. So, it is considered to be one of the most dangerous diseases all over the world.Although widely used in lipid lowering therapy, statins (even when administered at high doses) are frequently insufficient to achieve guideline-recommended LDL-C goals for many patients with hypercholesterolemia. Often over half of patients do not achieve LDL-C goal on the initial dose of statin and most of these patients do not reach goal neither after six months. Thus, a wide therapeutic gap exists between targets LDL-C levels and those typically achieved in clinical practice. A recent and more effective therapeutic strategy, is to treat the two main sources of cholesterol simultaneously (production of cholesterol, mainly in the liver, and absorption of cholesterol in the intestine) through dual inhibition of both cholesterol production and absorption with a complementary mechanism of action, by coadministering ezetimibe, a novel agent inhibiting cholesterol absorption, together with atorvastatin, which inhibits cholesterol production in the liver, as well as , enhancing efficacy of statin(atorvastatin) if compared with single inhibition of cholesterol production, afforded by statins alone furthermore side effects of statin(atorvastatin) may be reduced if reduction of its frequency dose .So, the aim of the work in this thesis is to study the formulation and evaluation of the suggested drug combination containing atorvastatin and ezetimibe in most suitable and most stable dosage form